In a nutshell This study tests whether a combination of ibrutinib (Imbruvica) and rituximab (Rituxan) is an effective treatment for CLL patients. This study concluded that this combination was effective in high-risk patients. Some background Chronic lymphocytic leukemia (CLL) is a blood and bone marrow disease. It often occurs during middle...
Read MoreRisk group-High risk Posts on Medivizor
